The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Transformation to pure-play Innovative Medicines company nears completion
The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health
The startup plans to provide free technology to dental clinics upon registration.
The country has been witnessing a progressive reduction in IMR, U5MR and NMR
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Subscribe To Our Newsletter & Stay Updated
